RxDoctor Payments Data

Jennifer Hucks, MD

Pulmonary Disease · Columbia, SCNPI 1699960294

Payments from drug & device makers

$650in general payments, 2019–2025

Across 17 payments — averaging $38.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Chiesi USA, Inc.$128
  • Regeneron Healthcare Solutions, Inc.$119
  • Mylan Specialty L.p.$109
  • Electromed, Inc.$79
  • Advanced Respiratory, Inc$43
  • Bard Peripheral Vascular, Inc.$38
  • plus $133 from 7 others

What the payments were for

  • Food & beverage$54183%
  • Education$10917%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$650 in reported general payments places this provider in the 25th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$112,741
Medicare patients
355
Services billed
1,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft27$703,548
UptraviSelexipag12$269,490
Trelegy ElliptaFluticasone/Umeclidin/Vilanter263$239,354
AdempasRiociguat12$170,157
OpsumitMacitentan12$148,047
Pirfenidone14$115,523
Breztri AerosphereBudesonide/Glycopyr/Formoterol110$80,462
RevatioSildenafil Citrate12$64,535
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr68$32,292
Breo ElliptaFluticasone/Vilanterol45$26,681
Spiriva RespimatTiotropium Bromide16$19,964
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$13,140
Albuterol Sulfate HfaAlbuterol Sulfate300$11,954
SymbicortBudesonide/Formoterol Fumarate20$8,653
DuleraMometasone/Formoterol17$8,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$35$170,15712 claims
MerckDulera$13$8,61417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →